Innovent Biologics has reported that efdamrofusp alfa, its investigational dual-target fusion protein for neovascular age-related macular degeneration, met the primary endpoint in the Phase 3 STAR study in China, showing non-inferior vision gains to aflibercept at 52 weeks while supporting extended dosing intervals in a large proportion of patients. The disclosure positions the candidate as a potential new long-acting anti-vascular endothelial growth factor option in a market where durability, clinic burden, and long-term retinal outcomes remain central competitive questions.
What makes this result more meaningful than a routine non-inferiority announcement is the combination of visual efficacy and dosing flexibility in the same dataset. In neovascular age-related macular degeneration, non-inferior best corrected visual acuity gains alone are no longer enough to differentiate a new entrant. Ophthalmologists and payers already understand that several anti-vascular endothelial growth factor agents can preserve or improve sight when patients remain on treatment. The commercial and clinical pressure point is whether a therapy can keep patients stable with fewer injections and fewer visits without giving back control of fluid or risking undertreatment. That is why Innovent Biologics’ emphasis on every-12-week and every-16-week maintenance, and the suggestion that some patients may be extendable to every 20 weeks, matters more strategically than the headline efficacy comparison alone.
Why durability rather than simple visual non-inferiority is the real competitive battleground in nAMD now
The neovascular age-related macular degeneration market has steadily shifted from a pure efficacy contest into a durability contest because real-world care rarely matches the discipline of registration trials. The treatment burden associated with intravitreal injections has long been one of the field’s biggest practical weaknesses. Patients are often elderly, monitoring visits are frequent, caregivers are involved, and adherence tends to deteriorate over time. A drug that can preserve visual outcomes while meaningfully reducing injection frequency does not merely offer convenience. It can potentially improve persistence, reduce clinic congestion, and make disease control more achievable outside ideal trial settings. Innovent Biologics is clearly trying to place efdamrofusp alfa inside that conversation rather than presenting it as just another anti-vascular endothelial growth factor molecule.
That said, durability claims in retina always demand careful interpretation. The STAR design used disease activity assessments at Weeks 16 and 20 to assign patients in the efdamrofusp alfa arm to every-16-week, every-12-week, or every-8-week dosing, while the aflibercept comparator remained on every-8-week maintenance after loading. This creates a clinically relevant comparison because it reflects the real objective of modern retinal care: not treating everyone the same, but identifying who can safely stretch. Yet it also means enthusiasm must be balanced with scrutiny around how disease activity was assessed, how retreatment thresholds were applied, and whether the extension performance holds through the second year. Year-one durability is commercially important, but year-two consistency is what begins to convince the field that longer intervals are not just a honeymoon effect.
What the dual-pathway design of efdamrofusp alfa may reveal about where retinal drug development is heading
Efdamrofusp alfa is not being positioned as a standard anti-vascular endothelial growth factor therapy. Innovent Biologics describes it as a bispecific fusion protein designed to inhibit vascular endothelial growth factor activity while also modulating complement through binding to C3b and C4b. That dual-pathway concept is where the scientific story becomes more interesting than the topline data release. The retinal field has been exploring whether angiogenesis alone fully explains disease progression and long-term retinal damage, or whether inflammatory and complement-mediated processes contribute to incomplete responses, tissue degeneration, or long-term anatomical decline. A drug built around both vascular leakage control and complement pathway involvement is effectively betting that future competition in retinal disease will not be won only by stronger drying power or longer pharmacokinetics, but by broader biological control.
This is where the macular atrophy signal, while early, becomes strategically valuable. Innovent Biologics reported a lower incidence of macular atrophy at Week 52 in the efdamrofusp alfa arm than in the aflibercept arm. That finding is not yet strong enough to carry a broad clinical claim on its own, especially from a press release-level disclosure without full statistical framing, subgroup detail, or peer-reviewed analysis. Still, it points to the exact kind of differentiation retinal developers want. Durable anti-vascular endothelial growth factor control is attractive, but a therapy that also appears to preserve retinal tissue more effectively over time would move the conversation from convenience to long-term disease modification. For now, this remains a potential advantage rather than a settled one, and the field will want fuller data before treating it as clinically established.
Why the STAR trial design looks commercially useful even if some uncertainties still matter for regulators
The STAR study appears well-sized for a pivotal program, enrolling 600 participants and using aflibercept as an active comparator, which is appropriate for a registration-oriented neovascular age-related macular degeneration trial. The primary endpoint, change from baseline in best corrected visual acuity at Week 52, is conventional and regulator-friendly. The presence of both treatment-naive and previously treated patients also gives the dataset some practical breadth, since retinal clinics do not operate in a purely first-line world. From a regulatory standpoint inside China, that architecture gives Innovent Biologics a credible basis for a New Drug Application. The company has already indicated that it plans to prepare such a filing.
Even so, trial strength is not the same thing as interpretive completeness. The press release does not provide the full non-inferiority margin discussion, confidence intervals, statistical hierarchy details for secondary endpoints, or granular safety breakdowns that specialists will want to inspect. It also references cross-trial comparison against faricimab, which may be commercially tempting but scientifically limited. Cross-trial durability tables can be suggestive, but they are not substitutes for head-to-head evidence because patient populations, retreatment criteria, imaging interpretation, and investigator behaviour can vary materially across programs. Regulators may be satisfied by the formal primary endpoint package, but clinicians and commercial decision-makers will look for fuller disclosures before deciding whether this candidate is merely competitive or genuinely category-shifting.
How efdamrofusp alfa could alter treatment economics and clinic workflows if the data hold up over time
In retinal medicine, fewer injections can translate into more than patient convenience. They can influence capacity planning, physician scheduling, injection room throughput, and hospital economics. A therapy that safely allows a large proportion of patients to move to every-12-week or every-16-week intervals can reduce operational strain in high-volume ophthalmology centres. In China, where scale and access dynamics can be especially important, a domestically developed longer-interval biologic could also carry strategic significance beyond clinical performance. It may help localize competition in a category historically shaped by multinational leaders, while giving clinicians another option for patients who struggle with visit burden.
However, adoption will not be automatic. Retina specialists tend to be conservative when changing injection patterns because undertreatment risks are visible and immediate. Any new product entering this space must not only show that patients can be extended, but also prove that disease control remains predictable, rescue rules are workable, and monitoring burden does not quietly rise even if injection burden falls. Reimbursement and pricing will also matter. If a longer-acting therapy carries a premium that is not matched by obvious system-level efficiencies or clinical confidence, uptake can slow. Manufacturing consistency, supply reliability, and post-launch physician education also become important in biologics-heavy ophthalmology markets. A good Phase 3 readout opens the door, but it does not guarantee formulary enthusiasm or rapid prescribing momentum.
What clinicians and industry observers are likely to watch next before treating this as a true market inflection point
The next stage of scrutiny will likely centre on complete data disclosure. The ongoing follow-up to 100 weeks matters because durability stories can strengthen or weaken in the second year. Observers will want to know whether the every-16-week group remains stable, how many patients step down to shorter intervals, whether anatomical dryness is consistently maintained, and whether the macular atrophy separation widens, disappears, or becomes statistically persuasive. Safety will also receive close attention, particularly intraocular inflammation patterns, immunogenicity considerations, and any signal that broader pathway modulation changes ocular risk in a meaningful way.
What is genuinely new here is not simply that Innovent Biologics produced another anti-vascular endothelial growth factor-adjacent asset. The more important development is that a China-developed ophthalmology biologic has generated late-stage data combining standard visual efficacy with an explicit durability and mechanistic differentiation narrative. What remains incremental is that non-inferiority against aflibercept has become a familiar threshold in retina, not a disruptive one by itself. The commercial future of efdamrofusp alfa will therefore depend on whether extended dosing proves robust in broader practice and whether the macular atrophy signal matures into something more than an intriguing side note. If those pieces strengthen, the candidate could become a meaningful domestic and possibly international contender in retinal disease. If they do not, the asset may still reach market, but more as a regional alternative than a field-defining advance.
For now, the STAR result gives Innovent Biologics something more valuable than a headline. It gives the Suzhou-headquartered drugmaker a credible place in one of ophthalmology’s most commercially attractive and clinically demanding conversations: how to make neovascular age-related macular degeneration treatment last longer without losing trust. In retinal medicine, that is where the real contest is.
Extended-interval nAMD therapy gets a new contender as Innovent Biologics posts Phase 3 STAR data added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →